Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The PAZOREAL non-interventional study to assess efficacy and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma (mRCC) treatment landscape

Date

09 Oct 2016

Session

Poster display

Presenters

Peter Goebell

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

P. Goebell1, C. Doehn2, C. Grüllich3, V. Grünwald4, T. Steiner5, R. Ehness6, M. Welslau7

Author affiliations

  • 1 Department Of Urology, University Erlangen, 91054 - Erlangen/DE
  • 2 Department Of Urology, Urologikum Lübeck, Lübeck/DE
  • 3 Department Of Medical Oncology, University of Heidelberg, Heidelberg/DE
  • 4 Clinic For Hematology, Hemostasis, Oncology, And Stem Cell Transplantation, Medical School of Hannover, 30627 - Hannover/DE
  • 5 Department Of Urology, HELIOS Klinikum Erfurt, Erfurt/DE
  • 6 Department Of Oncology, Novartis Pharma GmbH, Nuernberg/DE
  • 7 Onkologische Schwerpunktpraxis Am Klinikum, Onkologie Aschaffenburg, 63739 - Aschaffenburg/DE
More

Resources

Abstract 3352

Background

Renal cell carcinoma (RCC) is diagnosed in about 15,500 patients per year in Germany, with up to 60% of patients requiring systemic treatment in the metastatic setting. Vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) inhibitors are broadly used in mRCC therapy and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab was recently approved in Europe for use after previous therapy. The non-interventional PAZOREAL study is designed to observe the real-world use of first-line through third-line therapy in the evolving treatment environment.

Trial design

This is a prospective, non-interventional study that will evaluate the efficacy, tolerability, safety, and quality of life (QoL) in patients with mRCC treated with first-line pazopanib, second-line nivolumab or everolimus, or third-line everolimus after nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, and whose systemic treatment will either start with first-line pazopanib or continue with third-line everolimus after second-line nivolumab, are eligible. Treatment will follow the respective German drug labels. Patients' history, treatment, disease assessment, concomitant medication, adverse events, follow-up treatments, and survival will be documented. Variables will include the time on drug for documented therapies, overall survival, dosing parameters, safety, and QoL (assessed by EQ-5D-5L questionnaire). Recruitment of patients started in December 2015 and is planned to end in December 2018, with a goal of 450 documented patients at about 150 sites in Germany. Four interim analyses are planned, and the first analysis will be performed in April 2017. Immediately after approval of nivolumab in Germany, the study was opened for documentation of therapy sequences including in-label nivolumab treatment in the second-line setting.

Clinical trial identification

Legal entity responsible for the study

Novartis Pharma GmBH

Funding

Novartis Pharma GmBH

Disclosure

P. Goebell: Advisory boards: Bayer, Bristol-Myers-Squibb, Novartis, Pfizer, Janssen, Sanofi-Aventis Honoraria, Travel: Astellas, Bayer, Bristol-Myers-Squibb, Novartis, Pfizer, Janssen, Sanofi-Aventis C. Doehn: Consulting/Advisory board: Roche Honoraria: Amgen, Bayer, BMS, Novartis, Pfizer Stock: AstraZeneca. C. Grüllich: Consulting/Advisory Board: Novartis, Nierenzell CA Honoraria: Novartis, Nierenzell CA Research: Novartis. T. Steiner: Consulting/Advisory Board: Novartis, BMS Research: BMS Studienteilnahe. R. Ehness: Employment: Novartis Germany Stock: GSK, Novartis. M. Welslau: Consulting/Advisory Board: Novartis, GSK, Pfizer, BMS Honoraria: Novartis, GSK, Pfizer, BMS. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings